HiResolution Bionic Ear System
Advanced Bionics · Decision date Sep 4, 2026
What did the FDA approve?
FDA completed review of PMA supplement P960058/S177 for the HiResolution Bionic Ear System on September 4, 2026. The supplement requested approval to remove the non-tamperproof battery door in the external processor and replace it with a validated tamperproof door in the packaged configuration of the M Zn-Air Battery Pak (CI-5501).
This is a Special (Immediate Track) supplement classified as a process change involving manufacturer, sterilizer, packager, or supplier. The decision is limited to the battery door change; it is not a new approval of the whole system. The source statement reports the requested change but does not provide independent proof of safety or clinical effectiveness.
FDA approval order statement
The Center for Devices and Radiological Health (CDRH) of the Food and Drug Administration (FDA) has completed its review of your premarket approval application (PMA) supplement, which requested approval to remove the non-tamperproof battery door in the HiResolution Bionic Ear System external processor and replace it with a validated tamperproof door in the packaged configuration of the M Zn-Air Battery Pak (CI-5501).
- Regulatory pathway
- PMA supplement
- Supplement type
- Special (Immediate Track)
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Sep 4, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P960058/S177
- Regulatory pathway
- PMA supplement
- Applicant
- Advanced Bionics
- Product code
- MCM
- Decision code
- APPR
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, cochlear.
- Applicant
- Advanced Bionics
- Product code
- MCM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P960058. Subsequent supplements may change the device or its indications.
FDA decision timeline
P960058 · Original PMA
CLARION MULTI-STRATEGY COCHLEAR IMPLANT
P960058/S177 received
Application receipt date recorded by FDA.
P960058/S177 · FDA decision
Special (Immediate Track)
P960058/S178 · Related supplement
CLARION MULTI-STRATEGY COCHLEAR IMPLANT
Timeline entries are records held by MedtechLedger for P960058. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P960058
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Advanced Bionics | PMA approval | Jun 26, 1997 | FDA | |
CLARION MULTI-STRATEGY COCHLEAR IMPLANTP960058/S178 | Advanced Bionics | PMA supplement | Sep 18, 2026 | FDA |
Explore the linked device profile
Other records with product code MCM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MED-EL Cochlear Implant SystemP000025/S136 | Med-El Corp. | PMA supplement | Oct 9, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP840024/S099 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 22 Cochlear Implant SystemP890027/S067 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
Nucleus 24 Cochlear Implant SystemP970051/S244 | Cochlear Americas | PMA supplement | Sep 28, 2026 | FDA |
| Med-El Corp. | PMA approval | Aug 20, 2001 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Advanced Bionics
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 28515 Westinghouse Pl., Valencia, CA, 91355
Sources and methodology
- Original FDA record: P960058/S177
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




